Lifecore Biomedical Stock Forecast for 2023 - 2025 - 2030
Updated on 05/04/2024
Lifecore Biomedical Stock Forecast and Price Target
The average price target for Lifecore Biomedical's stock lately set by several renowned analysts is $6.00, which would result in a potential downside of approximately -6.1% if it reaches this mark by December 31, 2024. This estimation is based on a high estimate of $6.00 and a low estimate of $6.00. If you're looking for information on Lifecore Biomedical stock, consider checking out the forecasts for comparable firms such as NYSE:LW.
-6.10% Downside
Lifecore Biomedical Fair Value Forecast for 2023 - 2025 - 2030
In the last three years, Lifecore Biomedical's Price has grown by 100.00%, rising from $0.00 to $0.00. For next year, analysts predict Fair Value of $6.44, which would mean an increase of 100.00%. Over the next seven years, experts predict that Lifecore Biomedical's Fair Value will grow at a rate of 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| LW Stock Forecast | Lamb Weston Holdings | Buy |
17
|
$85.08 | Buy/Sell | $128.48 | 29.29% |
| JJSF Stock Forecast | J&J Snack Foods | Outperform |
18
|
$138.24 | Buy/Sell | $187.25 | 25.14% |
| TR Stock Forecast | Tootsie Roll Industries | - |
18
|
$33.39 | Buy/Sell | $13.73 | -100.00% |
| FDP Stock Forecast | Fresh Del Monte Produce | Buy |
16
|
$24.52 | Buy/Sell | $33.00 | 28.47% |
| DOLE Stock Forecast | Dole | Outperform |
14
|
$12.44 | Buy/Sell | $15.57 | 34.24% |
Lifecore Biomedical Revenue Forecast for 2023 - 2025 - 2030
In the last three years, Lifecore Biomedical's Revenue has decreased by 35.48%, from $160.07M to $103.27M. For next year, analysts predict Revenue of $125.31M, which would mean an increase of 21.34%. Over the next seven years, experts predict that Lifecore Biomedical's Revenue will grow at a rate of 41.87%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BGS Stock Forecast | B&G Foods | Underperform |
18
|
$11.39 | Buy/Sell | $9.57 | -12.20% |
| STKL Stock Forecast | SunOpta | Buy |
11
|
$5.61 | Buy/Sell | $9.00 | 60.43% |
| BJRI Stock Forecast | BJ's Restaurants | Outperform |
4
|
$34.68 | Buy/Sell | $32.80 | 15.34% |
.jpg)
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| HAIN Stock Forecast | The Hain Celestial Group | Outperform |
14
|
$6.80 | Buy/Sell | $12.33 | 47.06% |
| CVGW Stock Forecast | Calavo Growers | Outperform |
14
|
$28.28 | Buy/Sell | $37.00 | 16.69% |
| BH.A Stock Forecast | Biglari Holdings | - |
11
|
$750.00 | Buy/Sell | $0.00 | -100.00% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| SENE.A Stock Forecast | Seneca Foods | - |
14
|
$57.86 | Buy/Sell | $21.00 | -100.00% |
| ANIK Stock Forecast | Anika Therapeutics | Outperform |
10
|
$27.59 | Buy/Sell | $27.33 | 15.98% |
| FARM Stock Forecast | Farmer Bros. | Outperform |
11
|
$3.13 | Buy/Sell | $6.00 | 91.69% |
Lifecore Biomedical EBITDA Forecast for 2023 - 2025 - 2030
Lifecore Biomedical's EBITDA has seen impressive growth In the last three years, rising from $-1.27M to $-11.12M – a growth of 775.59%. According to 2 major analysts, Lifecore Biomedical's EBITDA will fall by 262.05% in the next year, reaching $18.02M. Professionals believe that By 2030, Lifecore Biomedical's EBITDA will fall to $30.53M– a 374.59% decrease from its current value.
Lifecore Biomedical EBIT Forecast for 2023 - 2025 - 2030
In the last three years, Lifecore Biomedical's EBIT has grown by 110.46%, rising from $-9.37M to $-19.72M. In the next year, 2 analysts estimate that Lifecore Biomedical's EBIT will decrease by 139.91%, reaching $7.87M. Over the next seven years, experts believe that Lifecore Biomedical's EBIT will grow at a rate of 209.49%.
Lifecore Biomedical EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last three years, Lifecore Biomedical's EPS has grown by 273.08%, rising from $-0.26 to $-0.97. For the next year, 2 analysts project Lifecore Biomedical's EPS to drop by 89.69%, reaching $-0.10. By 2030, professionals believe that Lifecore Biomedical's EPS will decrease by 128.35%, reaching $0.28 – a concerning trend for the company.
.jpg)